US research signal / 2026

Research Trials

A practical guide to public US trial records for ibogaine and noribogaine: what investigational status means, what a listing can show, and why enrollment is never guaranteed.

This page is for orientation, not treatment selection. Current status, eligibility, locations, and contacts belong to the individual registry record.

Behind-the-scenes research setting used to introduce US ibogaine trial information

Start with the public record

For US-based ibogaine or noribogaine research, the most reliable starting point is a current ClinicalTrials.gov study record. It can identify the study title, sponsor or collaborating institution, study phase, locations, recruitment status, eligibility criteria, outcome measures, and listed contact route. Those details can change; the registry entry, rather than a third-party summary, should be the working source.

Search records with both “ibogaine” and “noribogaine,” then filter by location, status, and condition. Some records may be active, not yet recruiting, recruiting, completed, terminated, or withdrawn. “Recruiting” still does not mean every interested person qualifies, and completed studies no longer enroll. For broader orientation on the US landscape, the site’s ibogaine access overview places research alongside the legal and practical limits people encounter.

Public registries are designed to make studies discoverable and traceable. The FDA’s overview of clinical research explains that clinical investigations are structured studies of investigational products; they are not the same thing as ordinary medical care.

02 / what a listing can establish

Read phase, endpoints, eligibility, and status together

Phase I

Early human research

Phase I studies commonly focus on dose, tolerability, pharmacokinetics, and monitored safety signals. A registry’s listed primary endpoints show what the protocol is built to measure; they do not establish benefit for an individual participant.

Phase II

Focused investigational questions

Phase II research may examine a defined population and pre-specified outcomes while continuing safety evaluation. Read the condition, intervention, outcomes, schedule, and planned enrollment as one protocol—not as a general availability notice.

Eligibility

Screening is part of access

Age ranges, diagnoses, medication requirements, substance-use criteria, medical exclusions, and visit commitments can all determine eligibility. Records can use technical language, so questions should go to the listed study team rather than an intermediary.

Locations

Site-specific participation

A sponsor may appear on a study record while individual sites have different timing or capacity. Geographic location, recruitment status, and site contacts should be checked on the registry before making travel or financial decisions.

STATUS CHECK: A record’s “last update posted” date and its recruitment status are useful signals, but neither guarantees that a site can evaluate a new inquiry today.

“Investigational” is not an approval

In this context, investigational means a drug is being studied under a research protocol and is not approved for routine marketing as a treatment. An Investigational New Drug application, often called an IND, is the FDA framework that permits specified clinical investigation when applicable. IND-authorized research is not a statement that the product is safe, effective, or generally available.

Ibogaine’s legal and regulatory context also matters. In the United States, ibogaine is a Schedule I controlled substance; the DEA controlled-substances schedule is a primary reference for that classification. Research authorization is a narrow, protocol-bound pathway rather than an exception for self-directed use or ordinary treatment access.

That distinction helps when reviewing pages about whether ibogaine is illegal, because a lawful study process and a marketed treatment claim are not interchangeable. It also helps separate research from descriptions of ibogaine clinics or from discussions of ibogaine in the USA, which may refer to very different settings.

04 / safety architecture

Why trial monitoring is a different environment

A regulated clinical study generally operates under a written protocol, informed consent process, eligibility screening, scheduled assessments, adverse-event reporting, and institutional review. The federal human-subject protections describe the oversight framework used for research involving people. Specific safeguards depend on the study and should be confirmed in its registry entry and consent materials.

This structure differs from an offshore clinic arrangement, where regulatory systems, screening rules, emergency capacity, product handling, follow-up, and legal recourse can vary by location and operator. That difference is especially important for people comparing where ibogaine treatment is available with research participation, or weighing information about treatment costs in Mexico. A trial is not an alternative booking channel, and a clinic is not automatically a research site.

Before an inquiry

Check the public record’s status, location, and inclusion/exclusion criteria. Do not stop prescribed medication or change care plans to try to fit a study without guidance from an appropriate licensed clinician.

During screening

Expect that screening may identify reasons not to participate. This is a safety function, not a judgment or a sign that another unregulated option is appropriate.

Keep the pathways separate

It is understandable to compare trial listings with information on ibogaine treatment centers, Utah treatment questions, or European ibogaine treatment. But these pages address access contexts, while a US trial record addresses a defined research protocol. Treat each source according to what it actually documents.

The same caution applies to claims about ibogaine therapy benefits, ibogaine for depression, and ibogaine for addiction treatment. A study may explore a question in one population and still be unable to provide an approved treatment pathway. For basic context on the compound’s history and terminology, the ibogaine entry on Wikipedia can be a useful orientation source, but study-specific facts should remain anchored to registry records.

Travel and recovery narratives need the same separation. Information about an ibogaine retreat in Mexico, possible ibogaine aftereffects, or an ibogaine street name does not establish a trial’s eligibility, safety procedures, or enrollment. For the site’s approach to comparing information categories without treating them as care recommendations, see the resource pathways and boundaries.

06 / common questions

Trial participation, plainly stated

Are US ibogaine studies approved treatment programs?

No. A study may be authorized to investigate a drug under an IND, but that does not make the drug an approved treatment or establish routine public access.

How can someone check eligibility and enrollment?

Use the study record on ClinicalTrials.gov, verify the recruitment status and eligibility criteria there, and contact the listed study team only through the registry information. The status can change between searches.

How do trial safeguards differ from offshore clinics?

A US clinical trial operates under a protocol with informed consent, eligibility screening, scheduled assessments, safety reporting, and research oversight. These controls are study-specific and should not be assumed outside that setting.

Where does policy fit into this picture?

Policy shapes which research pathways can exist and how controlled substances are handled. The site’s policy and access context explains why legal status, research authorization, and consumer-facing availability should not be collapsed into one idea.

Keep the signal clean

Use trial records for trial facts.

Confirm every current detail with the relevant registry and research site before acting. Research participation is voluntary, selective, and investigational.

Search trial records